Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.4K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

325
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
325
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.0K
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

69
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
69
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.7K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026
Same author

European Society of Cardiology updated curriculum for heart failure nurses: developed by the Heart Failure Association, in collaboration with the Association of Cardiovascular Nurses and Allied Professions of the European Society of Cardiology.

European journal of heart failure·2026
Same authorSame journal

Mineralocorticoid Receptor Antagonist Use in Contemporary Heart Failure Care.

Cardiac failure review·2026
Same author

Portopulmonary hypertension and serum endothelin-1 levels in patients with liver cirrhosis.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2026
Same author

Prevention of heart failure.

European heart journal·2026
Same author

Tricuspid Regurgitation: Pathophysiology, Risk Stratification, and Implications for Intervention.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Feb 25, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.9K

Practical Applications for Single Pill Combinations in the Cardiovascular Continuum.

Ferdinando Iellamo1,2, Karl Werdan3, Krzysztof Narkiewicz4

  • 1Dipartimento di Scienze Mediche, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy.

Cardiac Failure Review
|August 9, 2017
PubMed
Summary

Single-pill combination therapy improves cardiovascular disease treatment by increasing efficacy and patient adherence while reducing costs and side effects. This approach is established for hypertension and shows promise for ischemic heart disease and heart failure.

Keywords:
Anginaheart failurehypertensionischaemic heart diseasesingle pill combination

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K
Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.7K

Related Experiment Videos

Last Updated: Feb 25, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

8.9K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

5.5K
Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
07:20

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

Published on: February 10, 2023

1.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Cardiovascular disease treatment remains suboptimal despite new therapies.
  • Single-pill combination therapy offers potential advantages over monotherapy.
  • These benefits include increased efficacy, reduced adverse events, lower pill burden, and improved patient adherence.

Purpose of the Study:

  • To review the benefits and applications of single-pill combination therapy in cardiovascular disease management.
  • To highlight the efficacy of specific combinations, such as ivabradine and beta-blockers.

Main Methods:

  • Literature review and synthesis of existing studies on single-pill combination therapy.
  • Analysis of data regarding treatment efficacy, tolerability, and patient adherence.

Main Results:

  • Combination therapy is established for hypertension treatment, often with better tolerability than monotherapy.
  • The preventative polypill concept for ischemic heart disease requires further study.
  • Ivabradine and beta-blocker combinations show proven efficacy in stable angina and chronic heart failure.

Conclusions:

  • Single-pill combination therapy presents a promising strategy for optimizing cardiovascular disease management.
  • Further research is needed for preventative polypills, but specific combinations like ivabradine and beta-blockers are effective.
  • Improved adherence and tolerability are key advantages of this therapeutic approach.